MRP-L35 Inhibitors

Tetracycline and its derivative, doxycycline, are known to bind to the ribosomal subunits, obstructing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex, which in turn would hamper the function of MRP-L35 as part of this complex. Chloramphenicol exerts its effects by binding to the peptidyl transferase center of the mitochondrial ribosome, inhibiting the enzymatic activity essential for protein chain elongation, thereby affecting the role of MRP-L35 in peptide synthesis. Similarly, linezolid binds to the ribosomal RNA of the bacterial ribosome, which is akin to the mitochondrial ribosome due to shared evolutionary origins, thus inhibiting the initiation of translation. This binding can impede the proper functioning of MRP-L35 by disrupting the formation of the initiation complex. Macrolide antibiotics, such as erythromycin and roxithromycin, bind to the exit tunnel of ribosomes, which can cause a blockage that prevents the elongation of the nascent protein chain, implicating a role for MRP-L35 inhibition due to its proximity to the tunnel. Lincosamide antibiotics like clindamycin attach to the 50S subunit of the ribosome, interfering with the transpeptidation reaction, a necessary step in protein elongation that MRP-L35 is likely associated with. Rifampicin, though traditionally targeting bacterial RNA polymerase, can influence mitochondrial RNA synthesis due to structural similarities, thereby affecting MRP-L35's involvement in protein synthesis. Actinonin, a peptide antibiotic, hinders peptidyl deformylase, an enzyme involved in preparing newly synthesized peptides for subsequent translation steps, which would be critical for MRP-L35's functional participation in these processes. Puromycin causes premature chain termination by mimicking aminoacyl-tRNA, which would lead to incomplete proteins and interrupt the normal role of MRP-L35 in protein synthesis. Lastly, zidovudine, a nucleoside analog, is incorporated into mitochondrial DNA, potentially causing toxicity and mitochondrial dysfunction, which can have downstream effects on the mitochondrial protein synthesis and thus on the function of MRP-L35.